Skip to main content
logo
Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.710
-0.890 (-34.23%)
At close: Sep 3, 2026, 4:00 PM EDT
1.643
-0.067 (-3.89%)
Pre-market: Sep 4, 2026, 6:41 AM EDT

Aptevo Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----3.1112.29
Revenue Growth
-----74.67%185.26%
Cost of Revenue
----17.8818.99
Gross Profit
-----14.77-6.7
Selling, General & Admin
11.6911.7710.2211.7713.8714.7
Research & Development
15.214.5414.3817.11--
Operating Expenses
26.8926.3124.628.8813.8714.7
Operating Income
-26.89-26.31-24.6-28.88-28.64-21.4
Other Non Operating Income (Expenses)
0.480.350.470.58-1.53-8.01
EBT Excluding Unusual Items
-26.41-25.97-24.13-28.3-30.17-29.41
Gain (Loss) on Sale of Assets
---9.65--
Other Unusual Items
----37.18-
Pretax Income
-26.41-25.97-24.13-18.657.01-29.41
Earnings From Continuing Operations
-26.41-25.97-24.13-18.657.01-29.41
Earnings From Discontinued Operations
---1.241.010.95
Net Income
-26.41-25.97-24.13-17.418.03-28.46
Net Income to Common
-26.51-25.97-24.13-17.418.03-28.46
Net Income Growth
------
Shares Outstanding (Basic)
10----
Shares Outstanding (Diluted)
10----
Shares Change
7302.27%-----
EPS (Basic)
-29.72-82.30----
EPS (Diluted)
-29.72-82.30----
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-25.34-25.59-23.79-11.73-21.05-22.39
Free Cash Flow Per Share
-28.41-81.11----
Gross Margin
------54.52%
Operating Margin
-----919.75%-174.10%
Profit Margin
----257.77%-231.51%
Free Cash Flow Margin
-----676.01%-182.17%
EBITDA
-26.69-26.07-24.25-28.31-27.74-20.26
EBITDA Margin
------164.79%
D&A For EBITDA
0.20.240.350.570.91.14
EBIT
-26.89-26.31-24.6-28.88-28.64-21.4
EBIT Margin
------174.10%
SEC Filings: 10-K · 10-Q